The PKD Foundation is the only organization in the U.S. solely dedicated to finding treatments and a cure for polycystic kidney disease (PKD) and improving the lives of those it affects.

On April 24, 2018, the U.S. Food and Drug Administration (FDA) granted approval of tolvaptan to be the first treatment in the United States for adult patients with autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease (PKD).

Follow our progress on PKD research, treatments, clinical trials, and finding a cure.

Currently, there is no cure for PKD. However, various treatments can help manage symptoms and slow the progression of the disease. Research efforts continue to explore potential therapies and interventions aimed at finding a cure for PKD in the future.

The PKD Parents Community has been serving and connecting parents of children with ARPKD and ADPKD for nearly 25 years. It offers support, compassion, and guidance, helping connect families with experts and other local PKD families. Are you a PKD parent? Learn more today.

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common and serious genetic conditions. In ADPKD, fluid-filled cysts gradually develop and grow in both kidneys, eventually leading to kidney failure.

On April 24, 2018, the U.S. Food and Drug Administration (FDA) granted approval of tolvaptan to be the first treatment in the United States for adult patients with autosomal dominant polycystic kidney disease (ADPKD), the most common form of PKD.

We’re the only organization in the U.S. solely dedicated to finding treatments and a cure for polycystic kidney disease (PKD). We fund research, education, advocacy, support, and awareness on a national and local level.

Follow the Research and Help End PKD . Don’t miss an update; join our mailing list for the latest research in ending PKD.

Living with polycystic kidney disease (PKD) is a journey marked by resilience and determination. Each day, those with PKD navigate a path filled with unique challenges, from managing symptoms and treatment regimens to confronting uncertainties about the future.